Skip to main content
Fig. 3 | Journal of Neuroinflammation

Fig. 3

From: MCC950, a selective NLPR3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation

Fig. 3

Functional outcome after CA/CPR was improved in MCC950-treated mice. a Schematic diagram of the experimental design. Mice were subjected to CA/CPR or sham surgery. After 15-min reperfusion, mice received intraperitoneal (ip) injection of MCC950 (treated) or vehicle (control), followed by daily injection for 2 days. Behavioral tests were performed at the indicated time points. Data from sham-operated mice served as baseline references. b–d Functional outcome assessment on day 3 after CA/CPR included b neurologic scores, c rotarod test (two mice from the vehicle group were not subjected to this test due to severe sickness), and d open field test. e Survival rate. Data are presented as median or mean ± SEM (n = 5–10/group). *p < 0.05; **p < 0.01

Back to article page